The medical community and governments can no longer ignore the consequences of the promotion of medicines on prescribing.
Articles on Pharmaceutical marketing
Displaying all articles
Some industry-funded clinical trials show signs of being designed to market drugs rather than to test them for their safety and effectiveness. Detecting these studies remains difficult.
Aggressive marketing of prescription opioids by pharmaceutical companies provided doctors with scant information about potential harmful effects.
Too often, pharmaceutical companies and device manufacturers exert influence in how their products are tested in the research phase and recommended in the clinic.
Evidence shows that opioid manufacturers fund patient advocacy groups in Canada, distorting policies to protect public health.
This week’s annual Family Medicine Forum is an opportunity for your family doctor – to cave or resist in the face of Big Pharma sponsorship and marketing.
Top contributors
-
Associate professor, Department of Family and Community Medicine, University of Toronto; York University, Canada; University of Sydney
-
Professor in Pharmaceutical Policy, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Senior Research Manager, University of Sydney and Honorary Assistant Professor, Bond University
-
Assistant Professor of Technology Management, University of California, Santa Barbara
-
Assistant Professor of Management and Organizations, Cornell University
-
Master's Student in Technology Management, University of California, Santa Barbara
-
Associate Professor, Lawrence Bloomberg Faculty of Nursing, University of Toronto
-
Postdoctoral research fellow, Applied Ethics, University of British Columbia
-
Honorary Research Fellow, University of Bath
-
Lecturer in Family Medicine, Faculty of Medicine, L’Université d’Ottawa/University of Ottawa